Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Bafna Pharmaceuticals Limited ( (IN:BAFNAPH) ) is now available.
Bafna Pharmaceuticals Limited has completed the sale of its manufacturing unit located in Madhavaram, Chennai, to Navron Pharma Private Limited. This transaction, finalized on June 30, 2025, was approved by the company’s Board of Directors and shareholders, and it marks a strategic move to streamline operations. The sale, which is not a related party transaction, involved a consideration of Rs. 1,45,13,260 and represents a minor portion of the company’s revenue and net worth, contributing 0.08% and 1.55% respectively. This move is expected to impact the company’s operational focus and potentially enhance its financial positioning.
More about Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products. The company is based in Chennai, India, and is known for its manufacturing capabilities in the pharmaceutical sector.
Average Trading Volume: 1,038
Current Market Cap: 1.85B INR
For an in-depth examination of BAFNAPH stock, go to TipRanks’ Overview page.